These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 34088513)

  • 1. Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
    Sharma A; Singh M; Chauhan R; Malik PS; Khurana S; Mathur S; Kumar S; Sreenivas V; Kumar L
    Gynecol Oncol; 2021 Aug; 162(2):382-388. PubMed ID: 34088513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis.
    Sharma A; Malik PS; Khurana S; Kumar S; Bhatla N; Ray MD; Kumar L
    Indian J Med Res; 2019 Dec; 150(6):575-583. PubMed ID: 32048620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
    Dinkic C; Eichbaum M; Schmidt M; Grischke EM; Gebauer G; Fricke HC; Lenz F; Wallwiener M; Marme F; Schneeweiss A; Sohn C; Rom J
    Gynecol Oncol; 2017 Aug; 146(2):279-284. PubMed ID: 28528917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
    Richardson DL; Sill MW; Coleman RL; Sood AK; Pearl ML; Kehoe SM; Carney ME; Hanjani P; Van Le L; Zhou XC; Alvarez Secord A; Gray HJ; Landrum LM; Lankes HA; Hu W; Aghajanian C
    JAMA Oncol; 2018 Feb; 4(2):196-202. PubMed ID: 29242937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.
    Eichbaum M; Mayer C; Eickhoff R; Bischofs E; Gebauer G; Fehm T; Lenz F; Fricke HC; Solomayer E; Fersis N; Schmidt M; Wallwiener M; Schneeweiss A; Sohn C
    BMC Cancer; 2011 Oct; 11():453. PubMed ID: 22014006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
    McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
    BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer.
    Gulia S; Ghosh J; Bajpai J; Rath S; Maheshwari A; Shylasree TS; Deodhar K; Thakur M; Gupta S
    JCO Glob Oncol; 2020 Mar; 6():542-547. PubMed ID: 32228315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
    Pignata S; Lorusso D; Scambia G; Sambataro D; Tamberi S; Cinieri S; Mosconi AM; Orditura M; Brandes AA; Arcangeli V; Panici PB; Pisano C; Cecere SC; Di Napoli M; Raspagliesi F; Maltese G; Salutari V; Ricci C; Daniele G; Piccirillo MC; Di Maio M; Gallo C; Perrone F;
    Lancet Oncol; 2015 May; 16(5):561-8. PubMed ID: 25882986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Gupta R; Cristea M; Frankel P; Ruel C; Chen C; Wang Y; Morgan R; Leong L; Chow W; Koczywas M; Koehler S; Lim D; Luu T; Martel C; McNamara M; Somlo G; Twardowski P; Yen Y; Idorenyi A; Raechelle T; Carroll M; Chung V
    Cancer Treat Res Commun; 2019; 21():100155. PubMed ID: 31279962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.
    Lan CY; Wang Y; Xiong Y; Li JD; Shen JX; Li YF; Zheng M; Zhang YN; Feng YL; Liu Q; Huang HQ; Huang X
    Lancet Oncol; 2018 Sep; 19(9):1239-1246. PubMed ID: 30082170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
    Shah PD; Wethington SL; Pagan C; Latif N; Tanyi J; Martin LP; Morgan M; Burger RA; Haggerty A; Zarrin H; Rodriguez D; Domchek S; Drapkin R; Shih IM; Smith SA; Dean E; Gaillard S; Armstrong D; Torigian DA; Hwang WT; Giuntoli R; Simpkins F
    Gynecol Oncol; 2021 Nov; 163(2):246-253. PubMed ID: 34620496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
    Morgan RD; Banerjee S; Hall M; Clamp AR; Zhou C; Hasan J; Orbegoso C; Taylor S; Tugwood J; Lyon AR; Dive C; Rustin GJS; Jayson GC
    Gynecol Oncol; 2020 Mar; 156(3):545-551. PubMed ID: 31932108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
    Oza A; Kaye S; Van Tornout J; Sessa C; Gore M; Naumann RW; Hirte H; Colombo N; Chen J; Gorla S; Poondru S; Singh M; Steinberg J; Yuen G; Banerjee S
    Gynecol Oncol; 2018 May; 149(2):275-282. PubMed ID: 29454514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
    McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
    Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.
    Zsiros E; Lynam S; Attwood KM; Wang C; Chilakapati S; Gomez EC; Liu S; Akers S; Lele S; Frederick PJ; Odunsi K
    JAMA Oncol; 2021 Jan; 7(1):78-85. PubMed ID: 33211063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
    Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
    Hall MR; Dehbi HM; Banerjee S; Lord R; Clamp A; Ledermann JA; Nicum S; Lilleywhite R; Bowen R; Michael A; Feeney A; Glasspool R; Hackshaw A; Rustin G
    Gynecol Oncol; 2020 Dec; 159(3):692-698. PubMed ID: 33077258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.
    Schulte B; Mohindra N; Milhem M; Attia S; Robinson S; Monga V; Hirbe AC; Oppelt P; Charlson J; Helenowski I; Abbinanti S; Cehic R; Okuno S; Van Tine BA; Agulnik M
    Br J Cancer; 2021 Aug; 125(4):528-533. PubMed ID: 34050255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.
    Cirkel GA; Hamberg P; Sleijfer S; Loosveld OJL; Dercksen MW; Los M; Polee MB; van den Berkmortel F; Aarts MJ; Beerepoot LV; Groenewegen G; Lolkema MP; Tascilar M; Portielje JEA; Peters FPJ; Klümpen HJ; van der Noort V; Haanen JBAG; Voest EE;
    JAMA Oncol; 2017 Apr; 3(4):501-508. PubMed ID: 27918762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
    Kucukoner M; Isikdogan A; Yaman S; Gumusay O; Unal O; Ulas A; Elkiran ET; Kaplan MA; Ozdemir N; Inal A; Urakci Z; Buyukberber S
    Asian Pac J Cancer Prev; 2012; 13(8):3973-6. PubMed ID: 23098502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.